COMPANY PROFILE

NH TherAguix

Explore full profile

NH TherAguix, a clinical stage company – First nanomedicine for cancer, combining imaging and radiotherapy

Meylan, FranceFounded 2015Biotech & Life Sciences

Valuation $50–100M Last recorded · 2019

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About NH TherAguix

NH TherAguix operates in the healthcare sector, specializing in nanomedicine to enhance the efficacy of radiotherapy treatments. The company primarily serves oncology patients and healthcare providers by developing gadolinium-based nanoparticles that improve the precision and effectiveness of radiotherapy. These nanoparticles interact with X-rays to intensify the damage to tumor tissues, thereby improving patient outcomes. NH TherAguix's business model revolves around research and development, clinical trials, and partnerships with medical institutions. Revenue is generated through licensing agreements, grants, and potential future sales of their proprietary treatments. The company aims to extend the lifespan and quality of life for cancer patients by making radiotherapy more effective and less harmful to healthy tissues. Keywords: nanomedicine, radiotherapy, oncology, gadolinium, nanoparticles, tumor targeting, healthcare, clinical trials, cancer treatment, medical innovation.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2015
Headquarters: Meylan, France
Employees: 5
Open positions: None listed
Dealroom signal: 55.4/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Drug Development, Spinout, Biotech and Pharma, Radiotherapy, biotech medtech and e-health, Observatoire Deeptech, Woman Founder
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Apr 2019	$15M	$59M	Supernova Invest · Bpifrance	—
SPINOUT✓Other financing	Jan 2015	$0	—	PULSALYS · French National Centre for Scientific Research - CNRS	—

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

NH TherAguix website traffic

Latest recorded traffic for NH TherAguix is 20K monthly website visits, up 7042.9% over the last three months. NH TherAguix's team declined 50% over the past year.

Latest monthly visits20K 3-month web change+7042.9% 1-year team growth-50%

Monthly website visitsDec 2018–May 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
MTMnemo TherapeuticsDeveloping powerful cell therapies that create accessible cures for solid tumors and blood cancers. EnfiniT platform, a groundbreaking drug discovery engine	Paris, France	Low Activity	10	$83M	$330M
PHPhost’inA biopharmaceutical company focused on the discovery and development of N-glycosylation inhibitors	Montpellier, France	Operational
AFAelis FarmaBiotech company conducting research and development on innovative signaling specific drugs	Bordeaux, France	Operational
STSeekyo TherapeuticsA privately-owned biotech company developing a Smart Chemotherapy, selective to tumours, safe for patients	Saint-Maur-des-Fossés, France	Operational
MPMaaT PharmaDevelops a series of microbiome-based drugs targeting mortality and comorbidities associated with blood cancer treatments	Lyon, France	Operational
CECellectisDeveloping allogeneic CAR-T cells	Paris, France	Operational
OOOrakl OncologyTumor avatars to transform oncology drug development	Paris, France	Operational
OBOne BiosciencesOperating a ‘discovery engine’ leveraging single-cell technologies to identify new therapeutics for difficult-to-treat diseases	Paris, France	Operational